arrow_back
Medical Information
  • GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. © 2023 Gilead Sciences, Inc. All rights reserved. US-UNBP-2480 12/23

Cell therapy research.

Cell therapy is a unique therapeutic platform where a patient's own cells are the starting point to create the treatment. Cell therapy modifies a patient's own immune cells to target their cancer.

Research commitment
Clinical trials in progress
Scientific focus

Committed to patients living with blood cancers

Select a trial below to view additional details (trial brochure or clinicaltrials.gov)
Timeline is based on trial start dates.
The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.

2016
KITE-222

R/R AML

 
iMMagine-1

R/R MM

2017
ZUMA-22

2L+ high-risk FL

 
KITE-363 or KITE-753

R/R BCL

2022
ZUMA-23

1L high-risk LBCL

 
ZUMA-24

2L LBCL outpatient

2023
ZUMA-25

Basket rare B-cell malignancies

00

Clinical trials in progress

Cell therapy clinical trials actively recruiting.

Rollover trial for links to trial brochures and/or clinicaltrials.gov records.

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.

R/R AML
Phase 1 open-label, multicenter study evaluating the safety of KITE-222, an autologous anti-CLL-1 CAR T-cell therapy, in subjects with R/R AML
AML

KITE-222

R/R BCL
Phase 1 open-label, multicenter study evaluating the safety and efficacy of KITE-363 or KITE-753, autologous anti-CD19/CD20 CAR T-cell therapies, in subjects with R/R BCL
BCL

KITE-363 or KITE-753

2L+ high-risk FL
Phase 3 randomized, open-label, multicenter study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in patients with R/R FL
FL

ZUMA-22

1L high-risk LBCL
Adaptive Phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk LBCL
LBCL

ZUMA-23

2L LBCL outpatient
Phase 2 open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel concomitant with prophylactic steroids in patients with R/R LBCL in the outpatient setting
LBCL

ZUMA-24

Basket rare B-cell malignancies
Phase 2 open-label, multicenter, basket study evaluating the safety and efficacy of brexucabtagene autoleucel in adults with rare B-cell malignancies (R/R RT, R/R BL, R/R HCL, and R/R WM)
Rare b-cell

ZUMA-25

Scientific focus

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.
Scientific focus
CAR T cell therapy
Cell therapy manufacturing

Clinicaltrials.gov may not reflect the most up-to-date information on the trials shown.

NCT, national clinical trial

1. Gilead Sciences Inc. Third Quarter 2023 Resource Book. November 7, 2023. Available at: https://s29.q4cdn.com/585078350/files/doc_financials/2023/q3/GILD-Q323-Resource-Book-7-November-2023.pdf